Chimeric flaviviruses: novel vaccines against dengue fever, tick-borne encephalitis, and Japanese encephalitis - PubMed (original) (raw)
Review
Chimeric flaviviruses: novel vaccines against dengue fever, tick-borne encephalitis, and Japanese encephalitis
Ching-Juh Lai et al. Adv Virus Res. 2003.
Abstract
Many arthropod-borne flaviviruses are important human pathogens responsible for diverse illnesses, including YF, JE, TBE, and dengue. Live, attenuated vaccines have afforded the most effective and economical means of prevention and control, as illustrated by YF 17D and JE SA14-14-2 vaccines. Recent advances in recombinant DNA technology have made it possible to explore a novel approach for developing live attenuated flavivirus vaccines against other flaviviruses. Full-length cDNA clones allow construction of infectious virus bearing attenuating mutations or deletions incorporated in the viral genome. It is also possible to create chimeric flaviviruses in which the structural protein genes for the target antigens of a flavivirus are replaced by the corresponding genes of another flavivirus. By combining these molecular techniques, the DNA sequences of DEN4 strain 814669, DEN2 PDK-53 candidate vaccine and YF 17D vaccine have been used as the genetic backbone to construct chimeric flaviviruses with the required attenuation phenotype and expression of the target antigens. Encouraging results from preclinical and clinical studies have shown that several chimeric flavivirus vaccines have the safety profile and satisfactory immunogenicity and protective efficacy to warrant further evaluation in humans. The chimeric flavivirus strategy has led to the rapid development of novel live-attenuated vaccines against dengue, TBE, JE, and West Nile viruses.
Similar articles
- DNA vaccines for flaviviruses.
Putnak R, Porter K, Schmaljohn C. Putnak R, et al. Adv Virus Res. 2003;61:445-68. doi: 10.1016/s0065-3527(03)61012-2. Adv Virus Res. 2003. PMID: 14714440 Review. No abstract available. - Identifying Attenuating Mutations: Tools for a New Vaccine Design against Flaviviruses.
Khou C, Pardigon N. Khou C, et al. Intervirology. 2017;60(1-2):8-18. doi: 10.1159/000479966. Epub 2017 Sep 5. Intervirology. 2017. PMID: 28869941 Review. - Safety evaluation of chimeric Langat/Dengue 4 flavivirus, a live vaccine candidate against tick-borne encephalitis.
Pripuzova NS, Tereshkina NV, Gmyl LV, Dzhivanyan TI, Rumyantsev AA, Romanova LIu, Mustafina AN, Lashkevich VA, Karganova GG. Pripuzova NS, et al. J Med Virol. 2009 Oct;81(10):1777-85. doi: 10.1002/jmv.21587. J Med Virol. 2009. PMID: 19697399 - Current status of flavivirus vaccines.
Barrett AD. Barrett AD. Ann N Y Acad Sci. 2001 Dec;951:262-71. doi: 10.1111/j.1749-6632.2001.tb02702.x. Ann N Y Acad Sci. 2001. PMID: 11797783 Review.
Cited by
- Rational Development of Live-Attenuated Zika Virus Vaccines.
Adam A, Lee C, Wang T. Adam A, et al. Pathogens. 2023 Jan 28;12(2):194. doi: 10.3390/pathogens12020194. Pathogens. 2023. PMID: 36839466 Free PMC article. Review. - Envelope Protein Mutations L107F and E138K Are Important for Neurovirulence Attenuation for Japanese Encephalitis Virus SA14-14-2 Strain.
Yang J, Yang H, Li Z, Wang W, Lin H, Liu L, Ni Q, Liu X, Zeng X, Wu Y, Li Y. Yang J, et al. Viruses. 2017 Jan 21;9(1):20. doi: 10.3390/v9010020. Viruses. 2017. PMID: 28117725 Free PMC article. - Viral vectors for malaria vaccine development.
Li S, Locke E, Bruder J, Clarke D, Doolan DL, Havenga MJ, Hill AV, Liljestrom P, Monath TP, Naim HY, Ockenhouse C, Tang DC, Van Kampen KR, Viret JF, Zavala F, Dubovsky F. Li S, et al. Vaccine. 2007 Mar 30;25(14):2567-74. doi: 10.1016/j.vaccine.2006.07.035. Epub 2006 Aug 1. Vaccine. 2007. PMID: 16914237 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources